Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Descrição
Frontiers Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer
The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
Frontiers Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?
Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis
Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma
Considerations for First-Line Metastatic Melanoma: Which Treatment Is Best?
Ipilimumab Plus Nivolumab Improves Survival in Melanoma With Brain Metastases - Cancer Therapy Advisor
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - ScienceDirect
The Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Melanoma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
